<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983473</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-I:MICROSPA</org_study_id>
    <nct_id>NCT03983473</nct_id>
  </id_info>
  <brief_title>Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.</brief_title>
  <acronym>MICROSPA</acronym>
  <official_title>Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. Identification de Biomarqueurs de SPondylArthrite Chez Les Patients Atteints de Maladie de CROhn présents Dans le MICrobiote fécal.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Antoine University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients
      suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of
      patients will be analyzed: patients suffering from CD alone, patients suffering from SpA
      alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as
      a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS
      sequencing
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alpha and Beta diversity of Fecal bacteriome</measure>
    <time_frame>+ 6 months</time_frame>
    <description>Alpha (number of species) and Beta diversity (distribution of species)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha and Beta diversity of Fecal fungome</measure>
    <time_frame>+ 6 months</time_frame>
    <description>Alpha (number of species) and Beta diversity (distribution of species)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha and Beta diversity of Fecal virome</measure>
    <time_frame>+ 6 months</time_frame>
    <description>Alpha (number of species) and Beta diversity (distribution of species)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients suffering from established Crohn 's disease without spondyloarthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spondyloarthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with established spondyloarthritis without Crohn 's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn + spondyloarthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients suffering from both spondyloarthritis and Crohn 's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients without spondyloarthritis and Crohn 's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiota Sequencing</intervention_name>
    <description>virome, bacteriome, fungome NGS sequencing</description>
    <arm_group_label>Crohn + spondyloarthritis</arm_group_label>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_label>Spondyloarthritis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Patients will be recruited according to 3 groups:

          -  Patients with Crohn's disease and axial spondyloarthritis according to the criteria
             below.

          -  Patients with Crohn's disease (MC patients) with a diagnosis established according to
             clinical, biological criteria, radiological, endoscopic and / or histological studies
             for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and
             / or New York modified.

          -  Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on
             modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease.

          -  Patient with the ability to give free and express informed consent.

        Exclusion Criteria:

          -  History of colonic resection

          -  Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool
             collection (Temporary contraindication = removal possible before colic or first bowel
             preparation after the start of colonic preparation).

          -  Ostomy at the time of sampling

          -  BMI&gt; 30

          -  extreme diet

          -  unbalanced diabetes

          -  Pregnant woman

          -  Patient under guardianship, under curatorship or under the protection of justice
             Contacts/Locations Central Contact
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

